Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

CVS Health Corp Stock Research

CVS

72.57USD+1.42(+2.00%)Market Closed
Watchlist

Market Summary

USD72.57+1.42
Market Closed
2.00%

CVS Alerts

  • Big fall in earnings (Y/Y)

CVS Stock Price

CVS RSI Chart

CVS Valuation

Market Cap

93.0B

Price/Earnings (Trailing)

30.1

Price/Sales (Trailing)

0.27

EV/EBITDA

12.9

Price/Free Cashflow

5.26

CVS Price/Sales (Trailing)

CVS Profitability

EBT Margin

1.74%

Return on Equity

5.81%

Return on Assets

1.73%

Free Cashflow Yield

19%

CVS Fundamentals

CVS Revenue

Revenue (TTM)

339.2B

Revenue Y/Y

10.27%

Revenue Q/Q

4.27%

CVS Earnings

Earnings (TTM)

3.1B

Earnings Y/Y

-37.24%

Earnings Q/Q

-11.25%

Price Action

52 Week Range

64.62103.80
(Low)(High)

Last 7 days

0.4%

Last 30 days

7.2%

Last 90 days

2.2%

Trailing 12 Months

-28.3%

CVS Financial Health

Current Ratio

0.92

Debt/Equity

0.79

Debt/Cashflow

0.36

CVS Investor Care

Dividend Yield

3.18%

Dividend/Share (TTM)

2.31

Buy Backs (1Y)

2.36%

Diluted EPS (TTM)

2.39

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for CVS

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-08-31
Mandadi Tilak
sold (taxes)
-850,664
65.17
-13,053
evp, chief technology officer
2023-08-31
Shah Prem S
sold (taxes)
-228,616
65.17
-3,508
evp and co-president of retail
2023-08-03
Clark James David
sold
-1,930,000
74.9247
-25,759
svp, cont & chief acct officer
2023-05-18
DEPARLE NANCY ANN
acquired
99,598
69.31
1,437
-
2023-05-18
Finucane Anne A.
acquired
99,598
69.31
1,437
-
2023-05-18
MILLON JEAN PIERRE
acquired
99,598
69.31
1,437
-
2023-05-18
AGUIRRE FERNANDO
acquired
92,113
69.31
1,329
-
2023-05-18
Balser Jeffrey R.
acquired
92,113
69.31
1,329
-
2023-05-03
Lynch Karen S
bought
976,567
69.7548
14,000
president and ceo
2023-04-01
Lynch Karen S
sold (taxes)
-6,961,140
74.31
-93,677
president and ceo

1–10 of 50

Which funds bought or sold CVS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-21
Baystate Wealth Management LLC
added
22.26
54,530
451,769
0.04%
2023-09-21
Jefferies Group LLC
reduced
-58.47
-385,624
287,921
-%
2023-09-21
Halpern Financial, Inc.
unchanged
-
-430
5,738
-%
2023-09-20
BARCLAYS PLC
added
97.8
173,058,000
379,052,000
0.24%
2023-09-18
CAPE ANN SAVINGS BANK
added
1.49
-37,531
634,752
0.42%
2023-09-14
IMS Capital Management
added
2.77
-30,354
660,952
0.37%
2023-09-12
DAVIDSON KEMPNER CAPITAL MANAGEMENT LP
sold off
-100
-16,719,800
-
-%
2023-09-12
DCM Advisors, LLC
reduced
-38.16
-2,069,060
2,803,150
1.20%
2023-09-12
Farther Finance Advisors, LLC
reduced
-5.07
-52,071
393,770
0.09%
2023-09-07
ST GERMAIN D J CO INC
new
-
26,912,400
26,912,400
1.42%

1–10 of 48

Latest Funds Activity

Are funds buying CVS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CVS
No. of Funds

Schedule 13G FIlings of CVS Health

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
8.94%
117,533,372
SC 13G/A
Feb 07, 2023
blackrock inc.
7.4%
96,668,258
SC 13G/A
Feb 09, 2022
vanguard group inc
8.28%
109,236,922
SC 13G/A
Feb 01, 2022
blackrock inc.
7.1%
93,556,500
SC 13G/A
Feb 10, 2021
vanguard group inc
8.05%
105,383,923
SC 13G/A
Jan 29, 2021
blackrock inc.
7.1%
92,478,369
SC 13G/A
Feb 12, 2020
vanguard group inc
8.05%
104,808,202
SC 13G/A
Feb 05, 2020
blackrock inc.
7.2%
94,158,010
SC 13G/A

Recent SEC filings of CVS Health

View All Filings
Date Filed Form Type Document
Sep 21, 2023
8-K
Current Report
Sep 11, 2023
8-K
Current Report
Sep 08, 2023
3
Insider Trading
Sep 01, 2023
4
Insider Trading
Sep 01, 2023
4
Insider Trading
Aug 23, 2023
8-K
Current Report
Aug 17, 2023
8-K
Current Report
Aug 04, 2023
4
Insider Trading
Aug 04, 2023
13F-HR
Fund Holdings Report
Aug 03, 2023
144
Notice of Insider Sale Intent

Peers (Alternatives to CVS Health)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
473.0B
348.5B
3.40% -1.54%
22.41
1.36
13.69% 15.63%
93.0B
339.2B
7.15% -28.30%
30.1
0.27
10.18% -63.11%
91.1B
186.1B
2.70% 3.10%
13.64
1.92
3.72% 22.38%
65.7B
98.7B
2.62% 0.03%
23.41
0.71
10.45% 7.48%
38.5B
147.9B
7.94% -13.00%
14.2
0.26
7.12% 45.86%
MID-CAP
6.3B
937.9M
8.26% -1.16%
491.91
6.73
17.97% 120.64%
6.1B
4.1B
-5.40% 9.61%
25.5
1.48
11.23% 37.01%
5.2B
2.3B
3.17% 35.63%
86.23
2.28
2.85% -58.05%
2.8B
6.5B
-13.00% 16.88%
13.3
0.44
1.83% 10.70%
SMALL-CAP
1.9B
1.5B
-12.60% 56.43%
-148.05
1.25
12.20% -155.34%
1.4B
999.1M
-5.28% -6.03%
26.12
1.41
10.42% 21.37%
835.8M
3.0B
0.71% -13.03%
-8.11
0.28
11.66% -12.20%
136.4M
107.9M
-0.31% -40.30%
37.03
1.26
25.86% -9.15%

CVS Health News

Best Stocks
Comparison of Stock Performance Walgreens Boots Alliance Inc vs ....
Best Stocks,
5 hours ago
InvestorsObserver
Morningstar
Winsight Grocery Business
The Motley Fool
PR Newswire

Returns for CVS

Cumulative Returns on CVS

4.3%


10-Year Cumulative Returns

-1.0%


7-Year Cumulative Returns

0.1%


5-Year Cumulative Returns

9.0%


3-Year Cumulative Returns

Risks for CVS

What is the probability of a big loss on CVS?

58.1%


Probability that CVS Health stock will be more than 20% underwater in next one year

24.6%


Probability that CVS Health stock will be more than 30% underwater in next one year.

0%


Probability that CVS Health stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CVS drawdown profile look like?

Y-axis is the maximum loss one would have experienced if CVS Health was unfortunately bought at previous high price.

Drawdowns

Financials for CVS Health

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue2.5%339,204330,919322,467315,225307,860299,840292,111285,061278,323271,048268,706266,041263,795261,885256,776244,311226,991210,482194,579188,546187,242
Gross Profit--------------------29,29229,081
Operating Expenses-----38,09437,490--35,01634,748-34,35634,48033,85433,54131,50027,88024,70521,36819,33218,984
EBITDA-100.0%-12,23512,34710,74517,46017,26917,43514,27714,04714,36614,21115,20515,52613,36213,368------
EBITDA Margin-100.0%-0.04*0.04*0.03*0.06*0.06*0.06*0.05*0.05*0.05*0.05*0.06*0.06*0.05*0.05*------
Interest Expenses4.5%2,3932,2902,2872,3432,3792,4322,5032,5732,7022,8312,9072,9632,9792,9863,0353,0342,9612,8782,6193,6922,773
Earnings Before Taxes-26.6%4,3105,8695,8364,36110,96210,56810,53710,0759,7369,9619,77010,87911,2069,8378,9976,7656,5311,8751,4064,1134,276
EBT Margin-100.0%-0.02*0.02*0.01*0.03*0.03*0.04*0.04*0.03*0.04*0.04*0.04*0.04*0.04*0.04*------
Net Income-26.7%3,0914,2194,3113,3658,3798,1418,0017,5867,2127,4077,1797,9698,2757,2256,6344,4684,328-171-5943,1123,007
Net Income Margin-100.0%-0.01*0.01*0.01*0.03*0.03*0.03*0.03*0.03*0.03*0.03*0.03*0.03*0.03*0.03*------
Free Cashflow-100.0%-17,39213,45019,49815,86816,19415,74515,19111,61812,92813,42812,64113,62811,72210,391------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets4.5%250,071239,330228,275231,212230,279232,873233,052234,891231,164229,606230,715232,898235,495230,639222,449220,113218,904219,768196,456131,506133,290
  Current Assets-1.4%67,75668,70665,63368,34162,14261,48360,03560,84256,55955,71956,36959,21162,50658,95850,30248,18546,90147,85745,24371,98173,790
    Cash Equivalents-5.5%13,80714,61812,94517,19712,46311,61112,6919,8267,1195,5987,8549,53215,14510,3378,4085,4696,3386,1686,55341,82744,057
  Inventory-5.3%17,29118,26319,09018,05817,37518,16017,76017,39916,97917,61818,49617,47816,51916,97617,51616,02815,51115,44816,45014,81814,922
  Net PPE1.0%13,00112,87212,87312,62612,76412,84412,89612,77112,66412,61112,60612,34912,22112,14612,04411,65111,48311,34811,34910,41910,249
  Goodwill1442.3%91,2605,91778,15078,08678,56079,06079,12179,12179,55279,55279,55279,57980,05779,99379,74979,54879,48579,07578,67834,21634,220
Liabilities5.6%177,069167,750156,506160,201154,773158,733158,211160,273157,599158,442161,014163,786167,140165,165158,279157,180157,305159,762137,91394,88497,679
  Current Liabilities5.5%79,20675,05469,42172,40968,45769,78067,71964,70959,31160,10462,01762,04463,69459,56053,30352,54449,37650,63145,76229,46031,493
  Short Term Borrowings-1,000--------252---255-1,0704463,005720--
  Long Term Debt8.8%61,41956,45050,47650,84850,79752,06351,97156,83259,29459,27059,20761,552--64,699---71,444--
    LT Debt, Current-------------8,1925,8283,7813,7783,8943,8931,2652,1393,540
    LT Debt, Non Current-------------63,48165,73564,69964,20666,94167,88871,44460,74761,569
Shareholder's Equity1.6%72,72671,58071,46970,68375,73674,03475,38174,61873,56571,16469,70169,11268,35565,47464,17062,93361,59960,00658,54336,62235,611
  Retained Earnings1.9%58,86857,75356,39854,57158,71056,48854,99754,26453,33151,20349,64049,32848,76846,45545,10844,01743,13641,85940,91141,84340,965
  Additional Paid-In Capital--------------------32,36032,264
Shares Outstanding0.2%1,2821,2791,3001,3151,3131,3121,3221,3211,3191,3131,3101,3101,3091,3061,3021,3021,3011,2981,2951,0201,018
Minority Interest39.4%2761983003283223103063103213143123053333343063193173203184.004.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations2.3%20,51720,05216,17722,13418,53218,93618,26517,82714,18015,45215,86514,93215,98614,20512,84812,69310,8628,4588,8656,2507,764
  Share Based Compensation12.4%518461447479488486484458453391400386406435453463396339280233236
Cashflow From Investing-71.2%-19,800-11,568-5,047-6,368-6,410-5,387-5,261-5,055-5,578-5,804-5,534-5,009-4,468-4,045-3,339-44,529-44,334-44,045-43,285-2,696-2,495
Cashflow From Financing118.4%947-5,140-10,516-11,243-9,955-10,821-11,356-11,718-15,905-13,556-7,696-5,664-2,515-5,795-7,654-4,518-4,243-50536,81935,59736,504
  Dividend Payments1.9%3,0192,9642,9072,8482,7812,6912,6252,6092,6152,6282,6242,6312,6122,6062,6032,4622,3262,1792,0382,0382,039
  Buy Backs-0.1%3,5163,5183,5002,0002,0002,000---------------

CVS Income Statement

2023-06-30
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenues:    
Premiums$ 25,108$ 21,260$ 49,460$ 42,891
Net investment income274146608314
Total revenues88,92180,636174,199157,462
Operating costs:    
Cost of products sold53,53649,290104,99194,799
Health care costs21,78217,49042,23035,413
Restructuring charge49604960
Opioid litigation charge000484
Loss on assets held for sale0034941
Operating expenses9,8739,18719,45318,511
Total operating costs85,68775,967167,519149,248
Operating income3,2344,6696,6808,214
Interest expense6865831,2751,169
Other income(22)(43)(44)(85)
Income before income tax provision2,5704,1295,4497,130
Income tax provision6561,0901,3931,736
Net income1,9143,0394,0565,394
Net income attributable to noncontrolling interests(13)(10)(19)(11)
Net income attributable to CVS Health$ 1,901$ 3,029$ 4,037$ 5,383
Net income per share attributable to CVS Health:    
Basic (in dollars per share)$ 1.48$ 2.31$ 3.15$ 4.10
Diluted (in dollars per share)$ 1.48$ 2.29$ 3.13$ 4.06
Weighted average shares outstanding:    
Basic (in shares)1,2831,3131,2831,312
Diluted (in shares)1,2871,3211,2891,325
Dividends declared per share (in dollars per share)$ 0.605$ 0.55$ 1.21$ 1.10
Cost, Product and Service [Extensible List]ProductsProductsProductsProducts
Products    
Revenues:    
Revenues$ 60,539$ 56,794$ 118,686$ 109,316
Services    
Revenues:    
Revenues$ 3,000$ 2,436$ 5,445$ 4,941

CVS Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Assets:  
Cash and cash equivalents$ 13,807$ 12,945
Investments3,0802,778
Accounts receivable, net29,54627,276
Inventories17,29119,090
Assets held for sale620908
Other current assets3,4122,636
Total current assets67,75665,633
Long-term investments22,11421,096
Property and equipment, net13,00112,873
Operating lease right-of-use assets17,70317,872
Goodwill91,26078,150
Intangible assets, net30,11824,803
Separate accounts assets3,2673,228
Other assets4,8524,620
Total assets250,071228,275
Liabilities:  
Accounts payable13,36714,838
Pharmacy claims and discounts payable20,41719,423
Health care costs payable11,99810,142
Policyholders’ funds1,4111,500
Accrued expenses22,83118,745
Other insurance liabilities4,8661,089
Current portion of operating lease liabilities1,7061,678
Short-term debt1,0000
Current portion of long-term debt1,4021,778
Liabilities held for sale208228
Total current liabilities79,20669,421
Long-term operating lease liabilities16,60916,800
Long-term debt61,41950,476
Deferred income taxes4,5884,016
Separate accounts liabilities3,2673,228
Other long-term insurance liabilities5,6595,835
Other long-term liabilities6,3216,730
Total liabilities177,069156,506
Shareholders’ equity:  
Preferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding00
Common stock, par value $0.01: 3,200 shares authorized; 1,764 shares issued and 1,282 shares outstanding at June 30, 2023 and 1,758 shares issued and 1,300 shares outstanding at December 31, 2022 and capital surplus48,64948,193
Treasury stock, at cost: 482 shares at June 30, 2023 and 458 shares at December 31, 2022(33,933)(31,858)
Retained earnings58,86856,398
Accumulated other comprehensive loss(858)(1,264)
Total CVS Health shareholders’ equity72,72671,469
Noncontrolling interests276300
Total shareholders’ equity73,00271,769
Total liabilities and shareholders’ equity$ 250,071$ 228,275
Karen S. Lynch
65535
CVS Health Corporation provides health services in the United States. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. Its Pharmacy Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, clinical, and disease and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, plans offered on public health insurance and private health insurance exchanges, other sponsors of health benefit plans, and individuals. This segment operates retail specialty pharmacy stores; and specialty mail-order, mail-order dispensing, and compounding pharmacies, as well as branches for infusion and enteral nutrition services. The company's Retail/LTC segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products; and provides health care services through its MinuteClinic walk-in medical clinics. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. As of December 31, 2021, it operated approximately 9,900 retail locations and 1,200 MinuteClinic locations, as well as online retail pharmacy websites, LTC pharmacies, and onsite pharmacies. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.